New cancer Drug's interaction with common meds under microscope
NCT ID NCT06575933
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 study in 28 healthy adults examines how the experimental cancer drug calderasib (MK-1084) changes the way the body processes two common drugs: midazolam and digoxin. Researchers measure drug levels in the blood after giving these drugs with and without calderasib. The goal is to see if calderasib affects their breakdown, which could inform future dosing recommendations for people with non-small cell lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
calderasib (MK-1084)
What this could lead to
If successful, this study will help doctors understand how calderasib interacts with other drugs, leading to safer dosing guidelines for people with non-small cell lung cancer.
What could go wrong
This is an early-phase study in 28 healthy volunteers, not patients. It only measures drug levels, not whether calderasib works for cancer. Results may not predict real-world effects in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion ( Site 0001)
Tempe, Arizona, 85283, United States